Abiraterone acetate treatment lowers 11-oxygenated androgens
Open accessThe DOI matches its Crossref record; 35 of the 35 references it cites were found in a registry or an index.
Abstract
Context: The human adrenal is the dominant source of androgens in castration-resistant prostate cancer (CRPC) and classic 21-hydroxylase deficiency (21OHD). Abiraterone, derived from the prodrug abiraterone acetate (AA), inhibits the activity of cytochrome P450 17-hydroxylase/17,20-lyase (CYP17A1), the enzyme required for all androgen biosynthesis. AA treatment effectively lowers testosterone and androstenedione in 21OHD and CRPC patients. The 11-oxygenated androgens are major adrenal-derived androgens, yet little is known regarding the effects of AA administration on 11-oxygenated androgens. Objective: To test the hypothesis that AA therapy decreases 11-oxygenated androgens. Design: Samples were obtained from 21OHD or CRPC participants in AA or AA plus prednisone (AAP)-treatment studies, respectively. Methods: We employed liquid chromatography-tandem mass spectrometry (LC-MS/MS) to measure the 11-oxygenated androgens, 11β-hydroxyandrostenedione, 11-ketoandrostenedione, 11β-hydroxytestosterone, and 11-ketotestosterone, in plasma or serum samples from six 21OHD and six CRPC patients before and after treatment with AA or AAP, respectively. Results: In CRPC patients, administration of AAP (1000 mg/day AA with prednisone and medical castration) lowered all four 11-oxygenated androgens to below the lower limits of quantitation (<0.1–0.3 nmol/L), equivalent to 64–94% reductions from baseline. In 21OHD patients, administration of AA (100–250 mg/day for 6 days) reduced all 11-oxygenated androgens by on average 56–77% from baseline. Conclusions: We conclude that AA and AAP therapies markedly reduce the production of the adrenal-derived 11-oxygenated androgens, both in patients with high (21OHD) or normal (CRPC) 11-oxygenated androgens at baseline, respectively. Reduction of 11-oxygenated androgens is an important aspect of AA and AAP pharmacology.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Abiraterone also reduced serum levels of testosterone and 11-oxygenated androgens and urinary androgen metabolites121,122.”
From Management challenges and therapeutic advances in congenital adrenal hyperplasia (2022) · cites this paper as [122]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Abiraterone and Increased Survival in Metastatic Prostate Cancer
de Bono, J. S., Logothetis, C. J., Molina, A., Fizazi, K., North, S., Chu, L., Chi, K. N., Jones, R. J., Goodman, O. B., Saad, F., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1014618 · Cited by 4,407 · cited 1×
“combination with prednisone has been shown to improve survival in CRPC patients (9, 10) as well as when added to ADT prior to the development of CRPC (11, 12).”
BackgroundAbiraterone in Metastatic Prostate Cancer without Previous Chemotherapy
Ryan, C. J., Smith, M. R., de Bono, J. S., Molina, A., Logothetis, C. J., de Souza, P., Fizazi, K., Mainwaring, P., Piulats, J. M., Ng, S., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1209096 · Cited by 2,796
Abiraterone plus Prednisone in Metastatic, Castration-Sensitive Prostate Cancer
Fizazi, K., Tran, N., Fein, L., Matsubara, N., Rodriguez-Antolin, A., Alekseev, B. Y., Özgüroğlu, M., Ye, D., Feyerabend, S., Protheroe, A., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1704174 · Cited by 2,308 · cited 1×
“combination with prednisone has been shown to improve survival in CRPC patients (9, 10) as well as when added to ADT prior to the development of CRPC (11, 12).”
BackgroundAbiraterone for prostate cancer not previously treated with hormone therapy
James, N. D., de Bono, J. S., Spears, M. R., Clarke, N. W., Mason, M. D., Dearnaley, D. P., Ritchie, A. W. S., Amos, C. L., Gilson, C., Jones, R. J., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1702900 · Cited by 1,801 · cited 1×
“combination with prednisone has been shown to improve survival in CRPC patients (9, 10) as well as when added to ADT prior to the development of CRPC (11, 12).”
BackgroundSpeiser, P. W., Azziz, R., Baskin, L. S., Ghizzoni, L., Hensle, T. W., Merke, D. P., Meyer-Bahlburg, H. F. L., Miller, W. L., Montori, V. M., Oberfield, S. E., et al. (2010) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2009-2631 · Cited by 1,468
Speiser, P. W., Arlt, W., Auchus, R. J., Baskin, L. S., Conway, G. S., Merke, D. P., Meyer-Bahlburg, H. F. L., Miller, W. L., Murad, M. H., Oberfield, S. E., et al. (2018) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2018-01865 · Cited by 1,234
Self-citationAttard, G., Reid, A. H. M., Yap, T. A., Raynaud, F., Dowsett, M., Settatree, S., Barrett, M., Parker, C., Martins, V., Folkerd, E., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.15.9749 · Cited by 903
Cytochrome b 5 Augments the 17,20-Lyase Activity of Human P450c17 without Direct Electron Transfer
Auchus, R. J., Lee, T. C., & Miller, W. L. (1998) · Journal of Biological Chemistry · doi:10.1074/jbc.273.6.3158 · Cited by 541 · cited 5×
“The low expression of 3β-hydroxysteroid dehydrogenase/isomerase (3βHSD) in the ZR limits conversion of DHEA to active androgens, yet the human adrenal directly produces moderate amounts of androstenedione (A4) and very small amounts of testosterone (T) (2) (Figure 1).”
BackgroundSelf-citationPW, S., W, A., RJ, A., LS, B., GS, C., DP, M., HFL, M.-B., WL, M., MH, M., SE, O., et al. (2019) · Yearbook of Paediatric Endocrinology · doi:10.1530/ey.16.8.5 · Cited by 300
Self-citationAdrenarche—physiology, biochemistry and human disease
Auchus, R. J., & Rainey, W. E. (2004) · Clinical Endocrinology · doi:10.1046/j.1365-2265.2003.01858.x · Cited by 296 · cited 1×
“In prepubertal children, the expansion of the ZR and rise of adrenal-derived androgens manifest as the development of axillary and pubic hair during the process of adrenarche (3).”
BackgroundSelf-citation
Cited by
Congenital Adrenal Hyperplasia—Current Insights in Pathophysiology, Diagnostics, and Management
Claahsen - van der Grinten, H. L., Speiser, P. W., Ahmed, S. F., Arlt, W., Auchus, R. J., Falhammar, H., Flück, C. E., Guasti, L., Huebner, A., Kortmann, B. B. M., et al. (2022) · Endocrine Reviews · doi:10.1210/endrev/bnab016 · Cited by 556
Self-citationBasics of androgen synthesis and action
Naamneh Elzenaty, R., du Toit, T., & Flück, C. E. (2022) · Best Practice & Research Clinical Endocrinology & Metabolism · doi:10.1016/j.beem.2022.101665 · Cited by 199
Management challenges and therapeutic advances in congenital adrenal hyperplasia
Mallappa, A., & Merke, D. P. (2022) · Nature Reviews Endocrinology · doi:10.1038/s41574-022-00655-w · Cited by 113
Androgen excess: a hallmark of polycystic ovary syndrome
Wang, K., Lǐ, Y., & Chen, Y. (2023) · Frontiers in Endocrinology · doi:10.3389/fendo.2023.1273542 · Cited by 161
“However, its role in reducing 11-oxygenated androgens in PCOS needs further investigation (123).”
BackgroundSex differences in 11-oxygenated androgen patterns across adulthood
Davio, A., Woolcock, H., Nanba, A. T., Rege, J., O’Day, P., Ren, J., Zhao, L., Ebina, H., Auchus, R., Rainey, W. E., et al. (2020) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgaa343 · Cited by 76
Self-citation
Metadata
- Authors
- Wright, C., O’Day, P., Alyamani, M., Sharifi, N., & Auchus, R. J.
- Affiliations
- 1Division of Metabolism, Diabetes, and Endocrinology, Department of Internal Medicine
- 3Genitourinary Malignancies Research Center, Lerner Research Institute
- Cleveland Clinic (US)
- University of Michigan (US)
- Corresponding author
- Auchus, Richard J
- Venue
- European Journal of Endocrinology
- Publisher
- Oxford University Press (OUP)
- Published
- 2020-04
- Volume
- 182
- Issue
- 4
- Pages
- 413-421
- ISSN
- 0804-4643 (ISSN-L)
- 1479-683X
- PMC
- PMC7096060
- OpenAlex
- W3006285711
- Cited by
- 68
- References
- 35
- Citations by year
- 2026: 8 · 2025: 6 · 2024: 12 · 2023: 11 · 2022: 16 · 2021: 12 · 2020: 3
- FWCI
- 5.92
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- European Journal of Endocrinology (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- Funders
- National Cancer Institute (R01CA190289, R01CA172382)
- National Institute of General Medical Sciences (R01GM086596)
- National Center for Research Resources (UL1RR024986)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Prostate Cancer Treatment and Research
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Adrenal Hormones and Disorders
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Hormonal and reproductive studies
- Keywords
- abiraterone, 11-oxygenated androgens, 11β-hydroxyandrostenedione, 11-ketoandrostenedione, 11β-hydroxytestosterone, 11-ketotestosterone, castration-resistant prostate cancer, 21-hydroxylase deficiency, CYP17 inhibition, prednisone, androgen reduction
- MeSH terms
- Abiraterone Acetate, Adrenal Hyperplasia, Congenital, Adult, Androgens, Androstenes, Chromatography, Liquid, Drug Therapy, Combination, Humans, Male, Prednisone, Prostatic Neoplasms, Testosterone, Tandem Mass Spectrometry, Cytochrome P-450 Enzyme Inhibitors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Abiraterone acetate treatment lowers 11-oxygenated androgens. https://app.cochat.ai/papers/10.1530/eje-19-0905
- The paper
- Wright, C., O’Day, P., Alyamani, M., Sharifi, N., & Auchus, R. J. (2020). Abiraterone acetate treatment lowers 11-oxygenated androgens. European Journal of Endocrinology. https://doi.org/10.1530/eje-19-0905
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.